David J. Borges, Vice President of Finance and Chief Accounting Officer at Omeros Corp, disposed of 10,906 shares of the company for a total of $206,804 through two open-market transactions executed under a pre-arranged trading plan.
The first transaction on August 21 involved the sale of 10,000 shares at $18.95 each, while the second on August 24 covered 906 shares at $19.10 each. Both sales were conducted under a Rule 10b5-1 trading plan established on February 10, 2026.
Prior to the share sales, Borges exercised derivative securities to acquire 10,906 shares valued at $37,910. On August 21, he exercised options for 5,906 shares at $3.93 per share and 4,094 shares at $2.94 per share. A further 906 shares were acquired via option exercise on August 24 at $2.94 per share. The options vest in 48 equal monthly installments, with commencement dates of April 1, 2022, and April 1, 2023.
Omeros reported adjusted earnings of $0.02 per share in the second quarter, exceeding analyst expectations of a $0.25 per share loss. Revenue reached $28.5 million, surpassing the $12.67 million forecast. The company attributed the outperformance to the commercial launch of its newly approved drug, YARTEMLEA.
